| Patient | Lili Boulanger |
|---|---|
| Date of birth | 2004-08-21 |
| Identifiers | MRN HR-ET025-SYN; SSN (made up) 000-25-7731 |
| Document date | 2026-10-19 |
| Author | Odile Marchetti-Rowe, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Adult preventive visit; no new complaints. [S]
Ms. Boulanger, now 22, returns for her yearly preventive visit. Her Crohn disease is in remission on risankizumab every eight weeks, with her last injection a week ago. The follow-up ileocolonoscopy two weeks ago showed healed ulcers (SES-CD 2). She has one or two formed stools a day, no pain, and has regained her weight. Her periods have become regular again. She is composing most mornings and has a new choral work in rehearsal. She completed the health risk assessment before the visit. [S]
| Element | Detail |
|---|---|
| Visit | Adult preventive visit, age 22 |
| Active conditions | Ileocolonic Crohn disease in remission on risankizumab |
| Medicines | Risankizumab 360 mg every 8 weeks; vitamin D3 2000 units daily |
| Recent events | Ileocolonoscopy two weeks ago: endoscopic response, SES-CD 2 |
| Functional status | Independent; composing and rehearsing |
Health risk assessment. Completed by the patient before the visit and reviewed during the visit. [S]
| Domain | Finding |
|---|---|
| Self-rated health | Good, better than at any time she can remember |
| Psychosocial | Supportive friends and fellow musicians; feels safe at home; some worry about money from a year of reduced work |
| Behavioral | Never smoker; no alcohol; no drugs; walks daily; eating three meals with snacks |
| Sexual and reproductive health | Not sexually active; no pregnancy plans for the next few years; contraception discussed |
| Activities of daily living | Independent in all |
| Instrumental activities of daily living | Manages her own medicines, injections, money, and household |
| Home safety | Smoke detector working; wears a seat belt |
| Sleep | About eight hours a night |
| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | Weight regained; no fever or night sweats |
| Eyes | Negative | No red or painful eyes |
| Ears, nose, mouth, and throat | Negative | No mouth ulcers |
| Cardiovascular | Negative | No chest pain or palpitations |
| Respiratory | Negative | No cough |
| Gastrointestinal | Negative | One or two formed stools a day; no pain or blood |
| Genitourinary | Negative | Regular periods; no urinary symptoms |
| Musculoskeletal | Negative | No joint pain or swelling |
| Integumentary | Negative | No rash, tender nodules, or new moles |
| Neurological | Negative | No headaches or numbness |
| Psychiatric | Negative | Mood good; PHQ-2 score 0 |
11 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Acetaminophen 500 mg oral tablet, one or two tablets by mouth up to every 6 hours as needed for abdominal pain, no more than 3000 mg a day; no nonsteroidal anti-inflammatory drugs | One or two tablets up to every 6 hours as needed | Oral route | 2025-12-15 | active | S |
| Prednisone 20 mg oral tablet: 40 mg by mouth each morning, reduced by 5 mg each week over eight weeks, as a bridge until risankizumab takes effect | 40 mg each morning, tapering by 5 mg weekly | Oral route | 2026-01-28 to 2026-03-24 | completed | S |
| Risankizumab 600 mg in 10 mL intravenous infusion over at least one hour at weeks 0, 4, and 8 (induction) | One infusion every 4 weeks for three doses | Intravenous route | 2026-02-02 to 2026-04-26 | completed | S |
| Risankizumab 360 mg in 2.4 mL by subcutaneous on-body injector every 8 weeks (maintenance), from week 12 | One injection every 8 weeks | Subcutaneous route | 2026-04-27 | active | S |
| Ferric derisomaltose 1000 mg in 10 mL intravenous infusion, single dose | Single infusion | Intravenous route | 2026-02-02 to 2026-02-02 | completed | S |
| Cholecalciferol (vitamin D3) 2000 units oral tablet, one tablet by mouth once daily | One tablet once daily | Oral route | 2026-01-28 | active | S |
| Calcium carbonate 1250 mg (500 mg elemental calcium) oral tablet, one tablet by mouth once daily with food while on prednisone | One tablet daily with food | Oral route | 2026-01-28 to 2026-03-24 | completed | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-10-19 | Body height | 160 | cm | S |
| 2026-10-19 | Body weight | 51.4 | kg | S |
| 2026-10-19 | Body mass index (BMI) [Ratio] | 20.1 | kg/m2 | S |
| 2026-10-19 | Systolic blood pressure | 108 | mm[Hg] | S |
| 2026-10-19 | Diastolic blood pressure | 68 | mm[Hg] | S |
| 2026-10-19 | Heart rate | 70 | /min | S |
| 2026-10-19 | Respiratory rate | 14 | /min | S |
| 2026-10-19 | Body temperature | 36.6 | Cel | S |
| 2026-10-19 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-10-19 | Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] | 0 | {score} | S | ||
| 2026-10-19 | Total score [AUDIT-C] | 0 | {score} | S |
Vital signs recorded on 2026-10-19; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| Constitutional | Well-appearing; BMI 20.1 |
| Eyes | Conjunctivae clear |
| Mouth | No ulcers |
| Neck | No thyroid enlargement or nodes |
| Cardiovascular | Regular rhythm; no murmur |
| Respiratory | Clear |
| Abdomen | Soft, non-tender; no mass |
| Skin | No erythema nodosum; no suspicious lesions |
| Musculoskeletal | No joint swelling |
| Psychiatric | Bright and engaged |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Crohn disease of the terminal ileum and colon (ileocolitis), Montreal A2 L3 B1 without perianal disease, moderate to severe: deep ileal ulcers over 15 cm and patchy colonic ulcers, SES-CD 14, Harvey-Bradshaw Index 11; intestinal tuberculosis excluded by negative interferon-gamma release assay, normal chest X-ray, and biopsies negative for acid-fast bacilli, TB PCR, and mycobacterial culture; synthetic modern diagnosis linked to her documented chronic intestinal illness, whose historical diagnosis is not settled | active | confirmed | K50.80 | S — Synthetic diagnosis confirmed within the modern episode; her historical illness is documented (D), but whether it was intestinal tuberculosis or Crohn disease remains a retrospective interpretation (R) and is disputed. |
| Four months of crampy right lower abdominal pain, loose stools up to six times a day including at night, low-grade evening fevers, and loss of 6 kg; inflammatory markers raised; colonoscopy and small-bowel imaging booked | resolved | confirmed | R19.7 | S — Synthetic presenting concern at the index visit, superseded by the diagnosis; the documented symptoms of early 1915 are echoed (D). |
| Iron deficiency anemia from chronic intestinal blood loss and poor absorption (hemoglobin 10.6 g/dL, MCV 76, ferritin 9) | resolved | confirmed | D50.0 | S — Synthetic finding at presentation; corrected by intravenous iron. |
| Moderate protein-calorie malnutrition: BMI 17.6 after losing 6 kg (12 percent of body weight) in four months; albumin 3.3 g/dL | resolved | confirmed | E44.0 | S — Synthetic nutritional status at presentation; resolved with treatment and dietitian support. |
| Vitamin D deficiency (25-hydroxyvitamin D 18 ng/mL) | resolved | confirmed | E55.9 | S — Synthetic finding at presentation. |
| Long-term use of risankizumab, an immunosuppressive biologic, for Crohn disease | active | confirmed | Z79.620 | S — Synthetic treatment status. |
| Acute norovirus gastroenteritis on risankizumab, with mild dehydration; distinguished from a Crohn flare by the sudden onset, household contacts, and a positive stool PCR; resolved in three days | resolved | confirmed | A08.11 | S — Synthetic common infection that teaches the difference between infection and a flare in treated Crohn disease; it does not echo a documented illness. |
Personalized prevention plan. A written copy was given to the patient. [S]
| Service | Status | Detail |
|---|---|---|
| Influenza vaccine, 2026-2027 | Completed today | Inactivated vaccine given today; recommended yearly on biologic therapy |
| COVID-19 vaccine, 2026-2027 | Due | Recommended on immunosuppressive therapy; she will get it at her pharmacy next week |
| Pneumococcal vaccine | Up to date | PCV20 in January, before treatment; no further doses needed |
| Recombinant zoster vaccine | Up to date | Two doses completed, in January and April |
| Hepatitis B immunity | Up to date | Booster in January; anti-HBs protective in April |
| HPV vaccine | Up to date | Series completed in adolescence |
| Tetanus booster | Up to date | Tdap ten years ago at 12; next due now to within a year |
| Live vaccines (MMR, varicella) | Not indicated | Immune by serology; live vaccines are avoided on risankizumab |
| Cervical cancer screening | Completed today | First cervical cytology at 22, done today; women on immunosuppressive therapy may need closer screening, to be set by the result |
| Skin cancer prevention | Completed today | Sun protection advised; skin examination today normal |
| Chlamydia and gonorrhea screening | Not indicated | Not sexually active; offered when that changes |
| HIV, hepatitis B, and hepatitis C screening | Up to date | Negative before treatment in January |
| Bone health | Up to date | DXA in January within the expected range; vitamin D now normal; no repeat needed unless more steroids are required |
| Depression and anxiety screening | Completed today | PHQ-2 score 0 |
| Unhealthy alcohol and drug use screening | Completed today | AUDIT-C 0; no drug use |
| Tobacco use | Completed today | Never smoker; smoking worsens Crohn disease, and she was counseled never to start |
| Blood pressure screening | Completed today | 108/68 mmHg |
| Physical activity and diet counseling | Completed today | Daily walking, a varied diet now that she is in remission, and calcium from food |
Immunizations given today: Influenza vaccine, 2026-2027 season [S]
Guideline basis: ACG Clinical Guideline Update: Preventive Care in Inflammatory Bowel Disease. Am J Gastroenterol 2025;120:1447-1473 (2025); Adult Immunization Schedule by Medical Condition and Other Indication (2026); Medicare Preventive Services reference: visit templates, screening cascades, and documentation elements (2026); USPSTF A and B Recommendations (2026)
Follow-up: Cervical cytology result by portal message. COVID-19 vaccine at her pharmacy. Next risankizumab dose in seven weeks. IBD review in four months. [S]
Voluntary advance care planning discussion of about 15 minutes, with her consent, prompted by a chronic illness treated with immunosuppression. She named a close friend as her health care agent and will complete a written health care directive at home. She would want full treatment for any serious illness from which she could expect to recover and return to composing. [S]